Carasent
24,5
SEK
-1,21 %
1.659 følger denne virksomhed
CARA
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
-1,21%
+8,43%
+3,81%
+10,36%
+28,72%
+33,53%
+23,93%
+59,05%
+10,77%
Carasent is an IT company. The company delivers a wide range of products and services in communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security solutions. Customers are mainly found in health and care, finance, and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.
Læs mereMarkedsværdi
1,77 mia. SEK
Aktieomsætning
1,03 mio. SEK
Omsætning
267,75 mio.
EBIT %
-19,8 %
P/E
-
Udbytteafkast, %
-
Finanskalender
10.7
2025
Delårsrapport Q2'25
16.10
2025
Delårsrapport Q3'25
12.2
2026
Årsrapport '25
Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Redeye: Carasent - AI initiatives in focus
Carnegie Access: Carasent: Solid start to the year – Q1 review
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Carnegie Access: Carasent: Strong growth in Q1 – initial comment

Carasent, Audiocast with teleconference, Q1'25
Carasent AB (publ) – interim report Q1 2025
Carasent AB (publ) – Invitation to presentation of Q1 2025 results
Carnegie Access: Carasent: The scene is set for 2025 – Q1 preview
Carnegie Access: Analyspodden 326: Carasent & Carnegies analytiker Elvin Rolder
Carasent publishes Annual Report for 2024
Notice of Annual General Meeting in Carasent AB (publ)
The Administrative Court rejects the healthcare providers' appeal to remove the requirement for Millennium in primary care in VGR
Carnegie Access: Carasent: Impressions from Carnegie’s Healthcare Conference
Proposal for election of the board of Carasent AB (publ)
Redeye: Carasent - Back in Shape in 2024 – More to Come
Carnegie Access: Carasent: Well-positioned for 2025 – Q4 review
Carnegie Access: Carasent: Solid end to the year – Q4 initial
